Centene, Ascension to launch Medicare Advantage plan

The nation’s largest Catholic and non-profit health system has teamed up with another provider to launch a new Medicare Advantage (MA) plan.

Centene Corporation and Ascension singed a letter of intent to explore the joint venture for their respective systems and affiliates beginning in 2020.

Centene is a multi-national healthcare company that provides both government sponsored and commercial healthcare program services, focused on under-insured and uninsured populations. Ascension is a faith-based organization and the nation’s largest non-profit health system and the world’s largest Catholic health system.

"We are pleased to pursue this joint venture with Ascension to create a differentiating offering for Medicare Advantage across multiple markets," Michael Neidorff, chairman and CEO of Centene, said in a statement. "This joint venture will bring together two leaders with decades of experience across markets and creates an opportunity for scaled payer-provider collaboration. We share a commitment of serving the underserved and intend to leverage the best capabilities of both organizations to provide high quality, affordable healthcare to support the needs of low-income seniors.

The announcement comes at a time when MA enrollment continues to swell and more major health systems plan to launch their own plans. However, less than a third of executives planning to launch an MA plan feel confident their system can do it successfully, according to a recent poll.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.